Drug firm Lupin Ltd. on Tuesday said it has received approval from the U.S. health regulator to market Doxycycline capsules used to treat bacterial infections in the American market.
The drug firm has received tentative approval from the U.S. Food and Drug Administration for its abbreviated new drug application for Doxycycline capsules, 40 mg, a generic equivalent of Galderma Laboratories' Oracea capsules, Lupin said in a statement.
As per IQVIA MAT September 2022 data, Doxycycline capsules had estimated annual sales of $215 million in the U.S. market.
Essential Business Intelligence, Continuous LIVE TV, Sharp Market Insights, Practical Personal Finance Advice and Latest Stories — On NDTV Profit.
